Latest Breaking News On - Annual needham virtual healthcare - Page 1 : comparemela.com

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesGina mangiaracinaJennifer minai azaryMartin lehrContext therapeutics incExchange commissionDrug administrationCompany nasdaqTherapeutics reports first quarterInvestigational new drugRecent corporateAnnual needham virtual healthcarePrivate securities litigation reform actMonths ended marchRelations contact

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ I-Mab , a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated.

United statesSan diegoRaj kannanTyler ehlerJoe skeltonJohn hayslipAnnual needham virtual healthcare conferenceAnnual needham virtual healthcareSenior director

Foghorn Therapeutics to Participate in Needham s 23rd Annual Virtual Healthcare Conference

05.04.2024 - Company presentation and fireside chat on April 11th at 11:45 a.m. ETCAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) - Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that .

United kingdomFoghorn therapeutics incAnnual needham virtual healthcareGene traffic controlFoghorn therapeutics chartOghorn therapeutics kursOghorn therapeutics aktie

Foghorn Therapeutics to Participate in Needham s 23rd Annual Virtual Healthcare Conference -April 05, 2024 at 07:00 am EDT

Company presentation and fireside chat on April 11th at 11:45 a.m. ETCAMBRIDGE, Mass., April 05, 2024 Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class.

United kingdomKarin hellsvikPeter kelleherAdam silversteinAdrian gottschalkGreg dearbornFoghorn therapeutics incExchange commissionCompany annual report on formTherapeutics incAnnual needham virtual healthcareGene trafficChief executiveAnnual reportFoghorn therapeuticsLifesci advisors

Trevi Therapeutics to Participate in Upcoming April Events

NEW HAVEN, Conn., April 4, 2024 /PRNewswire/ Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic.

Comunidad autonoma de catalunaKatie mcmanusFarrell simonLisa delfiniRosalia scampoliEuropean pulmonary fibrosis foundation patient summitTrevi therapeutics incUs drug enforcement agencyAnnual needham virtual healthcareJennifer goodAnnual needham virtual healthcare conferenceExploring opportunitiesChief commercialTrevi therapeutics